Is CMPS a good stock to buy? We came across a bullish thesis on COMPASS Pathways plc on BioEquity Watch’s Substack. In this ...
Compass Pathways stock took a hit in early June. Lykos Therapeutics just got some extremely bearish news from regulators. Regulators being skeptical about Lykos' medicine could be bad for Compass. If ...
Hosted on MSN
Why Compass Pathways stock rocketed 40% today
Compass Pathways has already reported two positive phase 3 trials for treatment-resistant depression (TRD). The company's COMP360 synthetic psilocybin treatment could now be on a faster track for ...
Hosted on MSN
Why did Compass Pathways stock rocket higher today?
Phase 3 clinical trial data has been a success. COMP360 is the first traditional psychedelic to consistently deliver a highly statistically significant outcome. Results included maintaining a ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Nov 4 (Reuters) - Drug developer Compass Pathways (CMPS.O), opens new tab said on Tuesday it is pulling forward the expected launch of its experimental psilocybin-based depression therapy by 9 to 12 ...
It's been a long road for Compass Pathways (NASDAQ: CMPS) to prove that its treatment using psilocybin therapy for treatment-resistant depression (TRD) can be successful. It was back in 2018 when the ...
A White House Executive Order over the weekend has some healthcare company stocks soaring today. One big winner is Compass Pathways (NASDAQ: CMPS). Shares of the biotechnology company rocketed more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results